Eraxis Side Effects Center

Last updated on RxList: 9/30/2020
Eraxis Side Effects Center

What Is Eraxis?

Eraxis (anidulafungin) is an antifungal antibiotic that treats candida (yeast) infections in the blood, or in the stomach or esophagus.

What Are Side Effects of Eraxis?

Common side effects of Eraxis include:

  • flushing or hot flashes,
  • dizziness,
  • diarrhea,
  • constipation,
  • headache,
  • nausea,
  • vomiting, or
  • injection site reactions (pain, swelling, or irritation).

Tell your doctor if you have serious side effects of Eraxis including shortness of breath, dark urine, severe stomach or abdominal pain, yellowing eyes or skin, persistent nausea or vomiting, muscle weakness or spasm, vision changes, pain/redness/swelling of arms or legs, new signs of infection (e.g., fever, persistent sore throat), easy bruising or bleeding, fast/slow/irregular heartbeat, seizures, increased urination or thirst, or mental/mood changes.

Dosage for Eraxis

The recommended dose of Eraxis to treat candidemia and other candida infections is a single 200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter. The recommended dose to treat esophageal candidiasis is a single 100 mg loading dose on Day 1, followed by 50 mg daily dose thereafter.

What Drugs, Substances, or Supplements Interact with Eraxis?

Other drugs may interact with Eraxis. Tell your doctor all medications and supplements you use.

Eraxis During Pregnancy and Breastfeeding

During pregnancy, Eraxis should be used only when prescribed. It is unknown if this medication passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Eraxis (anidulafungin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Rosacea, Acne, Shingles, Covid-19 Rashes: Common Adult Skin Diseases See Slideshow
Eraxis Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver right away if you feel light-headed, itchy, warm, tingly, sweaty, or if you have chest tightness or trouble breathing.

Call your doctor at once if you have:

  • a light-headed feeling, like you might pass out;
  • trouble breathing;
  • little or no urination, dark urine, pain or burning when you urinate;
  • stomach pain and bloating;
  • easy bruising, unusual bleeding, purple or red spots under the skin;
  • low potassium--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling;
  • low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; o
  • (in a baby) severe drowsiness, fussiness, feeding problems, or vomiting.

Common side effects may include:

  • abnormal liver function tests;
  • low blood sugar (hunger, sweating, irritability, dizziness, feeling shaky);
  • sore or white patches in your mouth or throat;
  • low blood pressure, feeling light-headed;
  • anemia, bruising or bleeding, nosebleed;
  • fever;
  • stomach pain, indigestion, nausea, vomiting, diarrhea;
  • low potassium;
  • headache, trouble sleeping; or
  • rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Eraxis (Anidulafungin)

QUESTION

Ringworm is caused by a fungus. See Answer
Eraxis Professional Information

SIDE EFFECTS

The following most serious adverse reactions are described elsewhere in other labeling sections:

  • Hepatic Adverse Reactions [see WARNINGS AND PRECAUTIONS]
  • Anaphylactic and Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience In Adults

The safety of ERAXIS for Injection was assessed in 929 individuals, including 257 healthy subjects and 672 patients in clinical trials of candidemia, other forms of Candida infections, and esophageal candidiasis. A total of 633 patients received ERAXIS at daily doses of either 50 mg or 100 mg. A total of 481 patients received ERAXIS for ≥14 days.

Candidemia/other Candida Infections

Three trials (one comparative vs. fluconazole, two non-comparative) assessed the efficacy and safety of ERAXIS (100 mg) in patients with candidemia and other Candida infections.

The data described below reflect exposure to ERAXIS and fluconazole in 127 and 118 patients, respectively, with candidemia and other forms of invasive candidiasis, in the randomized, comparative trial of the efficacy and safety of ERAXIS to that of fluconazole. In ERAXIS-treated patients, the age range was 16-89 years, the gender distribution was 51% male and 49% female, and the race distribution was 72% White, 18% Black/African American, 9% other races. Patients were randomized to receive once daily IV ERAXIS (200 mg loading dose followed by 100 mg maintenance dose) or IV fluconazole (800 mg loading dose followed by 400 mg maintenance dose). Treatment was administered for at least 14 and not more than 42 days.

The number of patients with adverse reactions leading to discontinuation of study medication was 11.5% in the ERAXIS arm and 21.6% in the fluconazole arm. The most common adverse reactions leading to study drug discontinuation were multi-organ failure (2.3%) and systemic Candida infection (1.5%) in the ERAXIS arm.

Table 2 presents adverse reactions that were reported in ≥5% of subjects receiving ERAXIS or fluconazole therapy in this trial.

Table 2: Adverse Reactions Reported in ≥5% of Adult Patients Receiving ERAXIS or Fluconazole Therapy for Candidemia/other Candida Infections*, **

Adverse ReactionERAXIS
100 mg
N=131
Fluconazole
400 mg
N=125
N (%)N (%)
Subjects with a least one adverse reaction130 (99)122 (98)
Gastrointestinal disorders81 (62)72 (58)
  Nausea32 (24)15 (12)
  Diarrhea24 (18)23 (18)
  Vomiting23 (18)12 (10)
  Constipation11 (8)14 (11)
  Abdominal pain8 (6)16 (13)
General disorders and administration site conditions70 (53)76 (61)
  Pyrexia23 (18)23 (18)
  Edema peripheral14 (11)16 (13)
  Chest pain7 (5)6 (5)
Respiratory, thoracic, and mediastinal disorders67 (51)55 (44)
  Dyspnea15 (12)4 (3)
  Pleural effusion13 (10)11 (9)
  Cough9 (7)7 (6)
  Respiratory distress8 (6)2 (2)
Investigations66 (50)46 (37)
  Blood alkaline phosphatase increased15 (12)14 (11)
  White blood cell increased11 (8)3 (2)
  Hepatic enzyme increased7 (5)14 (11)
  Blood creatinine increased7 (5)1 (1)
Metabolism and nutrition disorders61 (47)61 (49)
  Hypokalemia33 (25)24 (19)
  Hypomagnesemia15 (12)14 (11)
  Hypoglycemia9 (7)10 (8)
  Hyperkalemia8 (6)14 (11)
  Hyperglycemia8 (6)8 (6)
  Dehydration8 (6)2 (2)
Vascular disorders50 (38)41 (33)
  Hypotension19 (15)18 (14)
  Hypertension15 (12)5 (4)
  Deep vein thrombosis13 (10)9 (7)
Psychiatric disorders48 (37)45 (36)
  Insomnia20 (15)12 (10)
  Confusional state10 (8)10 (8)
  Depression8 (6)5 (4)
Blood and lymphatic system disorders34 (26)36 (29)
  Anemia12 (9)20 (16)
  Thrombocythemia8 (6)1 (1)
  Leukocytosis7 (5)6 (5)
Skin and subcutaneous tissue disorders30 (23)32 (26)
  Decubitus ulcer7 (5)10 (8)
Nervous system disorders27 (21)31 (25)
  Headache11 (8)10 (8)
Musculoskeletal and connective tissue disorders27 (21)25 (20)
  Back pain7 (5)13 (10)
*A patient who experienced multiple reactions within a Body System or preferred term was counted one time for that class, one time for the preferred term and one time for “subjects with at least one adverse reaction”.
** This trial was not designed to support comparative claims for ERAXIS for the adverse reactions reported in this table.

Esophageal Candidiasis

The data described below reflect exposure to ERAXIS and fluconazole in 300 and 301 patients, respectively, with esophageal candidiasis in a randomized trial comparing the efficacy and safety of ERAXIS to that of oral fluconazole. In ERAXIS-treated patients, the age range was 18-68 years, the gender distribution was 42% male and 58% female and the race distribution was 15% White, 49% Black/African American, 15% Asian, 0.3 % Hispanic, 21% other races. Patients were randomized to receive IV ERAXIS (100 mg on day 1, followed by 50 mg per day) or oral fluconazole (200 mg on day 1, followed by 100 mg per day) for 7 days beyond resolution of symptoms (range, 14-21 days).

Twenty-eight (9%) patients in the ERAXIS arm and 36 (12%) patients in the fluconazole arm had adverse reactions related to study medication. The most common adverse reactions leading to study discontinuation were maculopapular rash (1 patient) for the ERAXIS arm. The most common adverse reactions leading to discontinuation were rash (1 patient) and increased AST (1 patient) for the fluconazole arm.

Table 3 presents adverse reactions that were reported in ≥5% of subjects receiving ERAXIS therapy.

Table 3: Adverse Reactions Reported in ≥5% of Adult Patients Receiving ERAXIS or Fluconazole Therapy for Esophageal Candidiasis*, **

Adverse ReactionERAXIS
50 mg
N=300
Fluconazole
100 mg
N=301
N (%)N (%)
Subjects with a least one adverse reaction239 (80)227 (75)
Infections and infestations115 (38)99 (33)
  Oral candidiasis15 (5)10 (3)
Gastrointestinal disorders106 (35)113 (38)
  Diarrhea27 (9)26 (9)
  Vomiting27 (7)30 (10)
  Nausea20 (7)23 (8)
  Dyspepsia20 (7)21 (7)
Blood and lymphatic system disorders55 (18)50 (17)
  Anemia25 (8)22 (7)
Metabolism and nutrition disorders50 (17)46 (15)
  Hypokalemia14 (5)17 (6)
General disorders and administration site condition49 (16)54 (18)
  Pyrexia27 (9)28 (9)
Nervous system disorders39 (13)36 (12)
  Headache25 (8)20 (7)
*A patient who experienced multiple reactions within a Body System or preferred term was counted one time for that class, one time for the preferred term and one time for “subjects with at least one adverse reaction”.
**This trial was not designed to support comparative claims for ERAXIS for the adverse reactions reported in this table.

Less Common Adverse Reactions in Adult Patients with Candidemia/other Candida Infections and Esophageal Candidiasis

The following selected adverse reactions occurred in <2% of patients:

Blood and Lymphatic: coagulopathy, thrombocytopenia
Cardiac: atrial fibrillation, bundle branch block (right), sinus arrhythmia, ventricular extrasystoles
Eye: eye pain, vision blurred, visual disturbance
General and Administration Site: infusion related reaction, peripheral edema, rigors
Hepatobiliary: abnormal liver function tests, cholestasis, hepatic necrosis
Infections: clostridial infection
Investigations: amylase increased, bilirubin increased, CPK increased, electrocardiogram QT prolonged, gamma-glutamyl transferase increased, lipase increased, potassium decreased, prothrombin time prolonged, urea increased
Nervous System: convulsion, dizziness
Respiratory, Thoracic and Mediastinal: cough
Skin and Subcutaneous Tissue: angioneurotic edema, erythema, pruritus, sweating increased, urticaria
Vascular: flushing, hot flushes, thrombophlebitis superficial

Clinical Trials Experience In Pediatric Patients With Candidemia/Invasive Candidiasis

The safety of ERAXIS was investigated in 68 pediatric patients from 1 month to less than 18 years of age with candidemia/invasive candidiasis in a prospective, open-label, non-comparative pediatric trial [see Clinical Studies]. Overall, the safety profile of ERAXIS in the pediatric patients 1 month and older was similar to that of adults.

Most Common Adverse Reactions

The most common adverse reactions occurring in ≥5% of pediatric patients receiving ERAXIS therapy in the clinical trial are displayed by body system in Table 4.

Table 4 Adverse Reactions Occurring in ≥5% of Pediatric Patients Receiving ERAXIS Therapy for Candidemia/other Candida Infections*,**

Adverse Reaction1 month to <2 years
N=19
2 to <5 years
N=19
5 to <18 years
N=30
Overall
N=68
n (%)n (%)n (%)n (%)
Subjects with a least one adverse reaction17 (90)14 (74)24 (80)55 (81)
Blood and lymphatic system disorders9 (47)3 (16)4 (13)16 (24)
  Anemia5 (26)2 (11)07 (10)
  Thrombocytopenia2 (11)1 (5)1 (3)4 (6)
Gastrointestinal disorders8 (42)8 (42)12 (40)28 (41)
  Diarrhea4 (21)2 (11)5 (17)11 (16)
  Vomiting4 (21)5 (26)2 (7)11 (16)
  Abdominal paina04 (21)2 (7)6 (9)
General disorders and administration site condition5 (26)6 (32)9 (30)20 (29)
  Pyrexia4 (21)3 (16)5 (17)12 (18)
Laboratory Investigations4 (21)4 (21)8 (27)16 (24)
  Alanine aminotransferase increased2 (11)2 (11)2 (7)6 (9)
  Aspartate aminotransferase increased2 (11)1 (5)1 (3)4 (6)
Metabolism and nutrition disorders3 (16)4 (21)6 (20)13 (19)
  Hypoglycemia1 (5)2 (11)1 (3)4 (6)
Respiratory, thoracic and mediastinal disorders5 (26)5 (26)5 (17)15 (22)
  Epistaxis1 (5)2 (11)3 (10)6 (9)
Skin and subcutaneous tissue disorders6 (32)5 (26)5 (17)16 (24)
  Rashb3 (16)1 (5)2 (7)6 (9)
* Reflects adverse reactions including those that started on or after first dose of anidulafungin through 6-week follow-up for patients who did not receive oral fluconazole, and those that started between first dose and last dose of anidulafungin for patients who received oral fluconazole.
** A patient who experienced multiple reactions within a Body System or preferred term was counted one time for that class, one time for the preferred term and one time for “subjects with at least one adverse reaction”.
a Includes such terms as: abdominal pain and abdominal pain upper.
b Includes such terms as: rash and rash generalized.

Other adverse reactions were reported in 2 or more pediatric patients and in less than 5% of the 68 pediatric patients treated with ERAXIS in the clinical trial:

Blood and Lymphatic System Disorders: pancytopenia, thrombocytosis, febrile neutropenia, leukopenia, neutropenia
Eye Disorders: Periorbital edema
Gastrointestinal Disorders: gastroesophageal reflux disease, abdominal distension, nausea, stomatitis, dry mouth
General Disorders and Administrative Site Conditions: chest pain, edema peripheral
Infections and Infestations: bacteremia, device related infection, gastroenteritis, lower respiratory tract infection, upper respiratory tract infection, urinary tract infection
Laboratory Investigations: gamma-glutamyltransferase increased, transaminases increased
Metabolism and Nutrition Disorders: hypocalcemia, hypokalemia, hyponatremia, hypoproteinemia
Musculoskeletal and Connective Tissue Disorders: back pain, pain in extremity
Nervous System Disorders: headache, tremor, seizure
Psychiatric Disorders: agitation
Respiratory, Thoracic and Mediastinal Disorders: hemoptysis
Vascular Disorders: hypotension

Post-Marketing Experience

The following adverse reactions have been identified during post approval use of anidulafungin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune: Anaphylactic shock, anaphylactic reaction, bronchospasm [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Eraxis (Anidulafungin)

© Eraxis Patient Information is supplied by Cerner Multum, Inc. and Eraxis Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors